The role of dextromethorphan in pain control

被引:83
作者
Weinbroum, AA
Rudick, V
Paret, G
Ben-Abraham, R
机构
[1] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Post Anesthesia Care Unit, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Anesthesiol & Crit Care, IL-64239 Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Fac Med, Chaim Sheba Med Ctr, Pediat Intens Care Unit, IL-64239 Tel Aviv, Israel
来源
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE | 2000年 / 47卷 / 06期
关键词
D O I
10.1007/BF03018952
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Purpose: To review the clinical benefits of dextromethorphan (DM) in pain management, describe its neuropharmacological properties. Source: A Medline search was made for experimental and clinical data on DM use from 1967 to date using keywords nociception, acute and chronic pain control, N-methyl-D-aspartate, antagonists, dextromethorphan. Principle findings: The 930 DM citations mostly described its antitussive, metabolic and toxicological aspects, animal studies and its possible role in minimizing post-brain ischemia complications in humans. The use of DM in acute pain revealed eight original studies involving 443 patients, as well as two preliminary reports and our own unpublished data on 513 patients. Most of the 956 patients had general anesthesia. Eight studies (154 patients) and one case report dealt with chronic pain management. This N-methyl-D-aspartate (NMDA) receptor antagonist binds to receptor sites in the spinal cord and central nervous system, thereby blocking the generation of central acute and chronic pain sensations arising from peripheral nociceptive stimuli and enabling reduction in the amount of analgesics required for pain control. DM attenuated the sensation of acute pain at doses of 30-90 mg, without major side effects, and reduced the amount of analgesics in 73% of the postoperative DM-treated patients, Studies in secondary pain models in healthy volunteers and in various types of chronic pain showed DM to be associated with unsatisfactory pain relief. Conclusion: DM attenuates acute pain sensation with tolerable side effects. Its availability in oral form bestow advantages over other NMDA antagonists.
引用
收藏
页码:585 / 596
页数:12
相关论文
共 75 条
[1]  
AANONSEN LM, 1987, J PHARMACOL EXP THER, V243, P9
[2]   SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF THE N-METHYL-D-ASPARTATE ANTAGONIST DEXTRORPHAN IN PATIENTS WITH ACUTE STROKE [J].
ALBERS, GW ;
ATKINSON, RP ;
KELLEY, RE ;
ROSENBAUM, DM .
STROKE, 1995, 26 (02) :254-258
[3]   SAFETY AND TOLERANCE OF ORAL DEXTROMETHORPHAN IN PATIENTS AT RISK FOR BRAIN ISCHEMIA [J].
ALBERS, GW ;
SAENZ, RE ;
MOSES, JA ;
CHOI, DW .
STROKE, 1991, 22 (08) :1075-1077
[4]   COEXISTENCE OF GLUTAMATE AND SUBSTANCE-P IN DORSAL-ROOT GANGLION NEURONS OF THE RAT AND MONKEY [J].
BATTAGLIA, G ;
RUSTIONI, A .
JOURNAL OF COMPARATIVE NEUROLOGY, 1988, 277 (02) :302-312
[5]   DEXTROMETHORPHAN - AN OVERVIEW OF SAFETY ISSUES [J].
BEM, JL ;
PECK, R .
DRUG SAFETY, 1992, 7 (03) :190-199
[6]  
BENSON WM, 1953, J PHARMACOL EXP THER, V109, P189
[7]   NITROUS-OXIDE ANALGESIA - RESEMBLANCE TO OPIATE ACTION [J].
BERKOWITZ, BA ;
NGAI, SH ;
FINCK, AD .
SCIENCE, 1976, 194 (4268) :967-968
[8]   DEXTROMETHORPHAN AND PARKINSONISM [J].
BONUCCELLI, U ;
DELDOTTO, P ;
PICCINI, P ;
BEHGE, F ;
CORSINI, GU ;
MURATORIO, A .
LANCET, 1992, 340 (8810) :53-53
[9]  
Caruso FS, 1998, CLIN PHARMACOL THER, V63, P139
[10]   OPIOID RESPONSIVENESS OF CANCER PAIN SYNDROMES CAUSED BY NEUROPATHIC OR NOCICEPTIVE MECHANISMS - A COMBINED ANALYSIS OF CONTROLLED, SINGLE-DOSE STUDIES [J].
CHERNY, NI ;
THALER, HT ;
FRIEDLANDERKLAR, H ;
LAPIN, J ;
FOLEY, KM ;
HOUDE, R ;
PORTENOY, RK .
NEUROLOGY, 1994, 44 (05) :857-861